Begin main content


Last Updated: August 1, 2019
Result type: Reports
Project Number: SR0630-000
Product Line: Common Drug Review

Generic Name: ixekizumab

Brand Name: Taltz

Manufacturer: Eli Lilly Canada Inc.

Indications: Ankylosing spondylitis

Manufacturer Requested Reimbursement Criteria1:

​For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

Submission Type: New Indication

Project Status: Pending

Call For Patient Input: August 1, 2019

Patient Input Closed: September 23, 2019

Anticipated Date: August 30, 2019

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback